- Home
- EXEL
EXEL
Exelixis Inc.
as 05-30-2025 4:00pm EST
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 9.8B | IPO Year: | 2000 |
| Target Price: | $38.76 | AVG Volume (30 days): | 3.9M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.20 | EPS Growth: | 237.58 |
| 52 Week Low/High: | $20.40 - $48.85 | Next Earning Date: | 05-13-2025 |
| Revenue: | $2,298,922,000 | Revenue Growth: | 24.49% |
| Revenue Growth (this year): | 10.39% | Revenue Growth (next year): | 10.74% |
Stock Insider Trading Activity of Exelixis Inc. (EXEL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Haley Patrick J. | EXEL | EVP, Commercial | May 20 '25 | Sell | $44.06 | 34,387 | $1,515,091.22 | 412,072 | |
| Aftab Dana | EXEL | CSO/EVP Disc & Trans Research | May 1 '25 | Sell | $39.00 | 1,508 | $58,812.00 | 693,181 | |
| Haley Patrick J. | EXEL | EVP, Commercial | Mar 3 '25 | Sell | $38.80 | 10,000 | $388,000.00 | 412,072 |
Latest Exelixis Inc. News
EXEL Breaking Stock News: Dive into EXEL Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Top 4 Value Stocks With Impressive PEG Ratios to Buy Now
Motley Fool
2 days ago
2 Top Stocks to Buy With Less Than $100
Zacks
3 days ago
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Zacks
8 days ago
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)
Zacks
8 days ago
Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy?
Zacks
8 days ago
Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock?
Zacks
8 days ago
EXEL vs. ARGX: Which Stock Is the Better Value Option?
Zacks
8 days ago
EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort
Compare EXEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EXEL Exelixis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.